Skip to main content
John Tisdale, MD, Internal Medicine, Bethesda, MD

JohnFTisdaleMD

Internal Medicine • Bethesda, MD

Hematology/Oncology

Senior Investigator/National Institutes of Health

Join to view full profile

Dr. Tisdale is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tisdale's full profile

Already have an account?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1996
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Internal Medicine, 1990 - 1994
  • Medical University of South Carolina
    Medical University of South CarolinaClass of 1990

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2004 - 2025

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2010

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Transfusion Support for Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation (1993–2010): Factors That Predict Intensity and Time to Transfusion Independ...  
    Richard W Childs, John F Tisdale, Transfusion

Abstracts/Posters

  • Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model
    John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
    John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
    John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease 
    60th American Society of Hematology Annual Meeting - 12/2/2018
  • Development of a Clinically Applicable Method for High-Efficiency Gene Correction of Plerixafor-Mobilized CD34+ Cells from Patients with Sickle Cell Disease 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease 
    60th American Society of Hematology Annual Meeting - 12/1/2018
  • Join now to see all

Press Mentions

  • Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
    Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta ThalassemiaJanuary 3rd, 2023
  • Health News | Experimental Gene Therapy Reverses Sickle Cell Disease for Years: Study
    Health News | Experimental Gene Therapy Reverses Sickle Cell Disease for Years: StudyJanuary 1st, 2022
  • Study Finds Experimental Gene Therapy Reverses Sickle Cell Disease for Years
    Study Finds Experimental Gene Therapy Reverses Sickle Cell Disease for YearsDecember 27th, 2021
  • Join now to see all

Grant Support

  • 14C As A Marker For Beta Cell Turnover In Adult HumansNational Center For Research Resources2011
  • Nonmyeloablative Allogeneic PBSC In Globin DisordersNational Heart, Lung, And Blood Institute2009–2011
  • Isolation, Characterization, And Transplantation Of Candidate Stem CellsNational Heart, Lung, And Blood Institute2009–2011
  • A Preclinical Large Animal Model For Globin Gene TransferNational Heart, Lung, And Blood Institute2009–2011
  • Development Of Improved Lentiviral Vectors For Human Gene Therapy ApplicationsNational Heart, Lung, And Blood Institute2009
  • Development Of Improved Lentiviral Vectors For Human Gene Therapy ApplicationsNational Heart, Lung, And Blood Institute2008
  • Isolation, Characterization, And Transplantation Of Candidate Stem CellsNational Institute Of Diabetes And Digestive And Kidney Diseases2007
  • A Preclinical Large Animal Model For Globin Gene TransferNational Institute Of Diabetes And Digestive And Kidney Diseases2007
  • Nonmyeloablative Allogeneic PBSC In Globin DisordersNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2007
  • Isolation, Characterization, And Transplantation Of CandNational Institute Of Diabetes And Digestive And Kidney Diseases2006
  • A Preclinical Large Animal Model For Globin Gene TransfeNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
  • Isolation, Characterization, And Transplantation Of StemNational Institute Of Diabetes And Digestive And Kidney Diseases2005

Dr. John Tisdale, Dr. John Tisdale, MD, Dr. J Tisdale, Dr. John F Tisdale